The mechanisms by which p53 prevents development of cancer are much more complicated than previously thought. Under normal conditions, p53 is involved in cell-cycle arrest, apoptosis, DNA repair, and inhibition of angiogenesis; it also promotes degradation of proteins through transcriptional regulation of certain target genes. Here we report the isolation of a novel transcriptional target of p53, designated p53RFP (p53-inducible RINGfinger protein), whose product has E3 ubiquitin ligase activity. Its expression was negatively correlated to that of p21 WAF1 protein; p53RFP is likely to play a role in the regulation of this protein, probably through interaction with, and ubiquitination of, p21
Introduction
The p53 tumor-suppressor gene is inactivated by deletion or mutations in approximately 50% of human cancers (Hollstein et al., 1994) . Its product functions as a transcription factor, regulating the expression of dozens of target genes in response to different cellular stresses. This protein exerts its tumor-suppressive activities through transcriptional activation of genes implicated in growth control, cell-cycle arrest, DNA repair, inhibition of angiogenesis, metastasis, redox regulation, protein degradation, and apoptosis (Hupp et al., 2000) .
Among the p53-target genes identified so far, p21 WAF1 , an inhibitor of cyclin-dependent kinase, is a well-known p53 mediator in arrest of the cell cycle at G1 (Harper et al., 1993) . GADD45 and a ribonucleotide reductase, p53R2, are involved in DNA repair, whereas p53AIP1, BAX, NOXA, KILLER/DR5, Fas, PIDD and are p53 targets that play significant roles in the p53-inducible apoptotic pathway (Vogelstein et al., 2000) . GML enhances the sensitivity of cells to anti cancer drugs . BAI1 inhibits angiogenesis in glioblastoma cells, and p53DINP1 regulates p53-dependent apoptosis through phosphorylation of p53 at Ser46 (Okamura et al., 2001) . p53 induces expression of its target genes in a heterogeneous pattern that depends on the level of p53 protein in a cell, the type of inducing agent or stress, and the type of cell (Zhao et al., 2000) . The transcriptional targets induced by p53 vary in expression level, timing, and biologic effects (Yu et al., 1999) . One must assume that many p53-inducible genes have yet to be identified and characterized. Here we report isolation and characterization of a novel p53-inducible gene, p53RFP (p53-inducible RING finger protein) and consider its possible function as an E3 ubiquitin ligase.
Results
We employed cDNA-microarray technology for this study in an attempt to isolate a large panel of candidate genes that would be induced by exogenous expression of wild-type p53 in a glioblastoma cell line (U373MG) containing mt-p53. Cy5-dCTP-labeled aRNA isolated from the cells transfected with Ad-p53 (green) and Cy3-dCTP-labeled aRNA isolated from cells with Ad-LacZ (red) were mixed and hybridized to a cDNA microarray consisting of 9216 human genes. By calculating the ratio of Cy3-Cy5 at six time points (0, 6, 12, 24 , and 48 h after infection), we evaluated genes that appeared to be activated by wild-type p53. One of them was an EST of 510 nucleotides (GenBank Accession no. R37808) that showed increased intensity in green color 12, 24, and 48 h after Ad-p53 infection (data not shown). Using this cDNA fragment as a probe, we performed Northernblot analysis of mRNAs isolated from U373MG cells infected by Ad-p53 or Ad-LacZ, and confirmed that a 5-kb transcript was induced in a p53-dependent manner as early as 12 h after infection (Figure 1a ), but its induction revealed a 6 h delay, compared to that of p21
WAF1
, suggesting a distinct regulation by the modified p53 between the transcript and p21 WAF1 as previously reported in another p53 target, p53AIP1 (Oda et al., 2000) .
We isolated the full-length cDNA using the EST fragment as a probe to screen a cDNA library constructed from mRNA of U373MG cells infected by Ad-p53. The major transcript consisted of 4770 nucleotides encoding a putative 303-amino-acid peptide. A database analysis using SMART, Pfam, and BLOCKS predicted a putative RING-IBR-RING finger motif ( Figure 1b) . Hence, we termed this novel gene p53RFP (p53-inducible RING finger protein). A search for homology in the public database revealed identity to parts of a genomic DNA sequence in a BAC clone from the short arm of chromosome 6 (GeneBank Accession number AL138725). When the cDNA sequence was compared to this genomic sequence, p53RFP proved to be composed of eight exons spanning an 80-kb genomic region ( Figure 1c ). Sequence data have been deposited with the DDBJ/EMBL/GenBank data library under Accession number AB076367.
We searched for a candidate p53-binding sequence(s) in the p53RFP gene and found 10 possible sites in promoter and intron 1, which revealed an 80% or higher match to the consensus p53-binding sequence proposed by el-Deiry et al. (1992) . Thus, we analysed the interaction of p53 with these candidate p53-binding sequences by the chromatin immunoprecipitation (ChIP) assay (Sasaki et al., 2002) . ChIP analysis was performed using an anti-p53 antibody to immunoprecipitate the DNA-binding p53 proteins and its associated genomic DNA. One genomic fragment flanking a candidate p53-binding sequence (p53BS1), but not other nine fragments including p53BS2, was amplified by PCR (Figure 2a ), suggesting that p53 protein was likely to bind to p53BS1 in vivo as a chromatin-p53 complex. Hence, we considered p53BS1 as a true p53-responsive site.
To further confirm that these potential p53-binding sequences were able to enhance p53-regulated transcription, we performed the reporter assay. The heterologous reporter vector was constructed by cloning a genomic fragment containing the p53-binding site, p53BS1 upstream of the minimal SV40 promoter in the pGL3-promoter vector (Luc-BS1-pro or Luc-BS2-pro, respectively). Transfection of the Luc-BS1-pro, Luc-BS2-pro, or the pGL3-promoter vector alone into H1299 (p53 null) cells revealed no enhancement of the luciferase activity. However, we observed more than 30-fold increase of the relative luciferase activity when we cotransfected the Luc-BS1-pro with the plasmid expressing wild-type p53 (Figure 2b, left) . To investigate the effect of p53BS1 on the native promoter of p53RFP, we cloned the DNA fragment including p53BS1 into the pGL3-basic vector (Luc-BS1-ba). Consistent with the result of Luc-BS1-pro, the luciferase activity of the Luc-BS1-ba was enhanced by 80-fold by wild-type p53 (Figure 2b, right) . Cotransfection of the Luc-BS1-ba construct with either mutant p53 or empty vector did not result in increase of the luciferase activity. Moreover, point mutations in the p53BS1 of p53RFP (Luc-BS1-2mt-pro and Luc-BS1-2 mt-ba) significantly abolished the transactivation by wild-type p53, indicating that p53BS1 was the functional p53-responsible site of p53RFP (Figure 2b ).
The notion was also supported by the fact that we were able to induce endogenous p53RFP mRNA in a p53-dependent manner. We treated HCT116 p53-wild type (p53 þ / þ ) and its derivative cells (p53À/À) lacking p53 with 1 mg/ml of adriamycin as well as MCF7 cells (p53 þ / þ ) with various genotoxic stresses such as 1 mg/ml of adriamycin, or exposure to g (50 Gy) or UV (10 J/m 2 ) radiation and carried out Northern blot analysis. In response to cellular stress, endogenous p53 (Figure 2c ). In addition, we were also able to demonstrate the interaction of endogenous p53 to the chromatin DNA containing p53BS1 in either of HCT116 or MCF7 cells treated with adriamycin by ChIP assay (Figure 2d ). These data, combined with those of Northern blotting and reporter assays, indicate that p53RFP is a bona fide target of p53. We generated a rabbit antiserum against p53RFP to examine endogenous p53RFP protein. However, the quality of this antibody was unlikely to be good enough Figure 2 p53RFP as a direct target of p53. (a) ChIP assay: U373MG cells were infected with Ad-p53 designed to express wild-type p53. Chromosomal DNA was crosslinked with associated proteins. Cells were lysed and sonicated, and then p53 was immunoprecipitated using anti-p53 (DO-7) antibody. Control precipitations were carried out in the condition of no antibody or that using anti-FLAG antibody in Ad-p53-infected cells, and also with anti-p53 (DO-7) in parental cells. Input chromatin represented a portion of the sonicated chromatin before immunoprecipitation was carried out. One fragment with possible p53-binding sequence (p53BS1) in the p53RFP gene was amplified. The other candidate sequence, p53BS2 was amplified in the input control, but not in the immunoprecipitated samples with an antibody against p53. The p21 WAF1 promoter with its p53-binding site was amplified as a positive control. (b) Luciferase assay: H1299 cells were cotransfected with indicated reporter constructs, with pRL-CMV as an internal control vector, and with plasmids designed to express either wild-type (wtp53) or mutant p53 (mtp53) or mock vector (pcDNA3.1 þ ). Luciferase activities of each reporter constructed relative to the pGL3-promoter vector or pGL3-basic vector are shown here. pGL3-promoter vector containing p53BS1 (Luc-BS1-pro) , point mutations in p53BS1 (Luc-BS1-2mt-pro), pGL3-promoter vector (promoter vector), pGL3-basic vector with p53BS1 (Luc-BS1-ba), point mutations in p53BS1 (Luc-BS1-2 mt-ba), pGL3-basic vector (basic vector). (c) Induction of endogenous p53RFP by DNA damage. HCT116 (p53 þ / þ ), HCT116 (p53 À/À ), and MCF7 (p53 þ / þ ) cells were treated with the indicated genotoxic agents (g radiation, UV or adriamycin ADR) for various periods of time, after which p53RFP, p21
, and b-actin mRNAs isolated from these cells were analysed by Northern blotting. (d) Regulation of p53RFP expression by endogenous p53. ChIP assay was carried out on adriamycin-treated (ADR þ ) or not treated (ADRÀ) HCT116 and MCF7 cell line, followed by PCR amplification. PCR amplified a genomic fragment flanking the p53-binding element of p53RFP, p53BS1. (e) Expression of endogenous p53RFP protein in H1299 (p53À/À) cells infected with Ad-p53. p53RFP protein was detected on Western blots by means of an anti-p53RFP polyclonal antibody. (f) A dose-dependent induction of p53RFP protein by Ad-p53 in H1299 cells. (g) Subcellular localization of p53RFP protein. COS-7 cells were transfected with a plasmid expressing p53RFP tagged with HA at the C-terminal. At 48 h after transfection, the fusion protein was stained with rabbit anti-HA antibody (FITC), and the Golgi apparatus was stained with anti-Golgi 58k antibody (Texas-Red). The two images were merged (p53RFP þ Golgi) and nuclei were stained with DAPI (blue). A Western blot (right) confirmed the expression of HA-tagged p53RFP in COS-7 cells p53RFP, a p53-inducible RING-finger protein C-C Ng et al to detect the physiological levels of endogenous p53RFP protein since we were able to detect a band of endogenous p53RFP protein by Western blotting only when it was strongly induced by infection of Ad-p53. As shown in Figure 2e and f, p53RFP was strikingly induced in a time-or dose-dependent manner by infection with Ad-p53, in either H1299 (p53À/À) or U373MG cells (data not shown). The PSORT II program predicted a Golgi transport motif in the Nterminal region and a transmembrane domain at the Cterminus. p53RFP that was ectopically expressed by transfection of a plasmid vector designed to express this protein tagged with hemaglutanin (HA) appeared mainly in the cytoplasm, plasma membrane of COS-7 cells, and in the Golgi apparatus, after counterstaining with anti-Golgi antibody ( Figure 2g ). The subcellular localization of endogenous p53RFP protein should be examined when we will obtain the better anti-p53RFP antibody in the future.
We cotransfected plasmid DNAs designed to express FLAG-tagged p53RFP and HA-tagged ubiquitin into H1299 cells. p53RFP was immunoprecipitated using anti-FLAG antibody and the precipitate was detectable with anti-HA antibody. A discrete laddering was observed in the banding pattern, indicating that p53RFP was polyubiquitinated (Mimnaugh et al., 1999) (Figure 3a,b) .
Accumulated evidence indicates that proteins containing RING-finger domains are likely to be involved in the ubiquitination pathway, as many of them have E3 ligase activity or function as essential cofactors of the E3 complex (Jackson et al., 2000; Joazeiro and Weissman, 2000) . p53RFP might be the second known example of an E3 ubiquitin ligase as a p53 target (the first being MDM2, a negative regulator of p53); we speculated that p53RFP might regulate p53 and/or p53-related molecules. To screen for a cognate substrate of p53RFP, we inhibited the induction of endogenous p53RFP by Adp53 using S-labeled antisense oligonucleotides, and examined their effects on expression of p53-related proteins and of p53 itself. Antisense oligonucleotides (AS1), compared to sense (SE1), clearly reduced the level of p53RFP protein 12 and 24 h after infection with Ad-p53. In concert with this reduction, the amount of p21 WAF1 was increased at 12 and 24 h by AS1, but expression levels of p53, MDM2, p53R2, CDK4, and p53DINP1 were unchanged ( Figure 3c ). To examine the effect of overexpressed p53RFP on the cellular level of p21
, we transiently transfected a plasmid DNA designed to express p53RFP, or mock plasmid, into WAF1 protein by enforced expression of exogenous p53RFP. HCT116 cells were transfected with p53RFP expression plasmid or mock vector, then exposed to 14 Gy of g radiation (g ray). Expression levels of p21 WAF1 protein were examined by Western blot at 24 and 48 h after exposure to g radiation. (e) 2D Western blot analysis. Cells were transfected with oligonucleotides, infected with Ad-p53 and harvested at 24 h after the infection. The protein spots of p21 WAF1 were compared between the two cells transfected with sense or antisense oligonucleotides. Protein spots labeled by Cy-5 transferred on the membrane were examined as a quantity control p53RFP, a p53-inducible RING-finger protein C-C Ng et al HCT116 cells and exposed to 14 Gy of g radiation. Enforced expression of p53RFP decreased the level of endogenous p21 WAF1 protein after DNA damage (Figure 3d ), supporting the results of our antisense experiment. Taken together, the results suggested that expression of p53RFP was negatively correlated to that of p21 WAF1 . In Figure 3d , although the protein levels of p21 WAF1 were reduced by overexpression of p53RFP, a detectable amount of p21 WAF1 protein still remained. Since several studies indicated the presence of several forms of p21 WAF1 protein that are modified by phosphorylation and ubiquitination (Cayrol and Ducommun, 1998; Rousseau et al., 1999) , we speculated that p53RFP might regulate some form(s) of p21 WAF1 that has different functions from other forms. To justify this notion, we performed Western blot analysis coupled with 2D electrophoresis. As expected, there were several forms of p21 WAF1 depicted as independent spots (Figure 3e) . However, the intensity of all spots of p21 WAF1 protein detected by anti-p21 WAF1 antibodies in cells treated with antisense (AS1) was higher than that with sense oligonucleotides (SE1). These results indicated that p53RFP might play a pivotal role in the stability of all forms of p21 WAF1 protein and that the amount of p21 WAF1 is likely to be important for cell-cycle regulation.
Our observations that p53RFP encoded an E3 ubiquitin ligase or a subunit of E3 ligase complex, and that p53RFP might negatively regulate the expression of p21 WAF1 protein, prompted us to suspect that p53RFP might interact with p21 WAF1 and ubiquitinate it as a substrate, to promote its degradation. To test this hypothesis, we first looked for interaction between p53RFP and p21 WAF1 . The H1299 cell line was cotransfected with plasmid DNAs to express HAp53RFP and p21
; 24 h later, the cell lysates were isolated for immunoprecipitation experiments. Protein complexes including p53RFP or p21 WAF1 were precipitated from the lysates by anti-HA or anti-p21 WAF1 antibodies, respectively. The presence of p21 WAF1 or p53RFP in each complex was examined by immunoblotting with the reciprocal antibody. As shown in Figure 4a , anti-p21 WAF1 antibody clearly detected the specific band of p21 WAF1 in the protein complex immunoprecipitated by anti-HA antibody. Moreover, the precipitates produced by anti-p21 WAF1 contained p53RFP protein too, as a band detected by anti-HA antibody (Figure 4b ), a clear indication that overexpressed p53RFP and p21 WAF1 did, in fact, interact in vivo. The results were supported by an in vitro binding assay using recombinant GST-fused p53RFP (Figure 4c) . Furthermore, coimmunoprecipitation occurred when MG132, a proteasome inhibitor, was added, but was significantly reduced, in the absence of MG132. These results suggested that the interaction between p53RFP and p21 WAF1 prompted rapid degradation of either or both proteins in the proteasome system. p53RFP, a p53-inducible RING-finger protein C-C Ng et al
To determine whether p53RFP and p21 WAF1 could interact under physiological conditions, we sought to examine the endogenous proteins. However, as expression levels of p53RFP and p21 WAF1 are normally quite low, we induced endogenous p53RFP and p21
proteins by infection with Ad-p53, because both proteins are inducible in a p53-dependent manner. Cell lysates were isolated 24 h after infection and examined for expression of p53RFP and p21
. As shown in Figure 4d , both endogenous proteins were expressed at significant levels although expression of p53RFP seemed to be much lower than that of p21
. The protein complex including p53RFP was precipitated from these lysates by anti-p53RFP antibody (Figure 4d, bottom) . As shown in Figure 4d (top), the complex actually contained p21 WAF1 protein as well. These results showed that endogenous p53RFP indeed interacts with p21 WAF1 in vivo. To test whether p53RFP could function as a ubiquitin-protein ligase and promote the conjugation of ubiquitins to p21 WAF1 , in vitro ubiquitination was examined. As shown in Figure 5a , the amount of ubiquitinated GST-p21 protein was increased after incubation with His-p53RFP recombinant protein, rabbit reticulocyte lysate, ubiquitins, and ATP. The results suggested that p53RFP in fact had the ubiquitinprotein ligase activity for p21 WAF1 . Using MCF7 cells containing normal p53 protein, we established the cell line in which the expression of p53RFP was conditionally regulated in a tetracyclinedependent manner. As expected, p53RFP protein was expressed in the MCF7 cells in the absence of doxycycline, while it was not in the presence of doxycycline (Figure 5b) . We reasoned that, if p21 WAF1 is a true target of p53RFP, p53RFP may affect the cell cycle only when the cells suffer genotoxic stresses, resulting in increase of expression levels of p21 WAF1 . Indeed, we did not observe any remarkable change of cell cycle in the MCF7 cells, regardless of the presence or absence of doxycycline (data not shown). To examine the effect of p53RFP expression on the cell-cycle regulation by p21 WAF1 in response to cellular stresses such as DNA damage, the cells were treated with 1 mg/ ml adriamycin for 2 h after withdrawal of doxycycline. The treatment with adriamycin led to significant induction of p21 WAF1 mRNA as well as its protein in the cells treated with doxycycline (Figure 5b and c, Dox þ ). However, in the absence of doxycycline, the stress could induce much less p21 WAF1 protein in the same cells in spite of elevation of its mRNA levels, suggesting that the existence of p53RFP protein might reduce the expression level of p21 WAF1 protein (Figure 5b  and c, DoxÀ) . The expression levels of p53, MDM2, Cyclin E, p53R2, and PCNA proteins were unchanged in the same cells regardless of the presence or absence of p53RFP protein (Figure 5b , Dox þ and DoxÀ). These results were consistent with the notion that p53RFP may be involved in ubiquitination pathway, resulting in the degradation of p21 WAF1 protein. Moreover, the cells untreated with doxycycline showed the significant increase of the cells at the S phase at 24 h (8.5 vs 6.5%) and 48 h (9.4 vs 5.9%), and those of sub-G1 (28.4 vs 6.0%) at 72 h after the cellular stress, compared to the doxycycline-treated cells, implying the failure of cellcycle arrests that resulted in apoptosis-induction. MCF7 cells contain the wild-type p53 protein, implying that adriamycin-induced DNA damage might activate endogenous p53 protein in these cells, leading to the induction of endogenous p53RFP as well as p21 WAF1 . However, we failed to detect any bands of endogenous p53RFP in the ADR-treated MCF7 with doxycycline ( Figure(5b, Dox þ ) , and we failed to detect increase of apoptotic cells in these cells (Figure 5c , Dox þ ). We speculate two reasons to these questionable points. One is, the quality of anti-p53RFP antibody may not be good as mentioned in Figure 2 . The other is, 1 mg/ml adriamycin may not be severe enough to induce endogenous p53RFP in MCF7 cells as supported by the result of Figure 2c , in which p21 WAF1 mRNA was remarkably induced by 1 mg/ml of adriamycin, whereas the induction of p53RFP mRNA was much less than that of p21 WAF1 . These data, taken together, suggest that p53RFP protein might be, in part, involved in ubiquitination and degradation of p21 WAF1 protein, resulting in the release of the arrested cells from G1 phase and induction of cell death (Figure 5d ).
Discussion
p53RFP encodes a novel protein containing a putative RING-IBR-RING domain, as well as a transmembrane domain at the C-terminus. RING-finger domains are features of a large group of proteins with diverse cellular functions that include apoptosis, cell-cycle control, signal transduction, protein-protein interaction, and prevention of oncogenesis. Moreover, accumulated evidence has shown that proteins containing the RING-finger domain are likely to be involved in the ubiquitination pathway, many of them having E3 ligase activity or functioning as essential cofactors of the E3 complex.
Among the E3 enzymes with RING-finger domains identified so far, not many have transmembrane domains as well. Rma1 is the only known E3 ubiquitin ligase with a membrane-anchoring sequence at the C terminus (Matsuda et al., 2001) , whereas Hrd1/Der3 is an integral membrane protein with an N-terminal membrane-spanning region and a C-terminal RINGfinger motif that plays a role in ER-associated degradation (Bordallo et al., 1998) . Parkin, another molecule with a RING-IBR-RING domain, functions as an E3-ubiquitin ligase that binds an E2-ubiquitin-conjugating enzyme, UbcH8, to promote degradation of the synaptic vesicle-associated protein, CDCrel-1 (Zhang et al., 2000) . The human homolog of Drosophila ariadne (HHAR1) and UbcH7-associated protein (H7-AP1), each encoding RING finger and IBR domains, interact with UbcH7, an E2 enzyme. A recent study suggests that RING-IBR-RING proteins might be involved in ubiquitination pathway (Marin and Ferrus, 2002) . MDM2 is a RING-finger-dependent ubiquitin protein ligase for itself as well as for p53; E3 is known to accelerate the ubiquitination of its substrates and to be self-ubiquitinated as well (Fang et al., 2000) . We have demonstrated here that p53RFP is polyubiquitinated, probably signifying that it functions as an E3 ligase. E3s bind cognate substrates but they do not determine the outcome of ubiquitin(s) tagging. Ubiquitin conjugation (ubiquitination) is recognized as a multifunctional signaling mechanism. Polyubiquitination is a signal for destruction of proteins by 26S proteasomes, for endocytosis leading to proteolysis in the lysosome, and for DNA repair, whereas monoubiquitination signals endocytosis, protein sorting, subnuclear trafficking, and gene expression (Pickart, 2001) .
In the experiments reported here, inhibition of p53RFP expression using antisense oligonucleotides resulted in accumulation of p21 WAF1 protein. Furthermore, overexpression of exogenous p53RFP in the HCT116 cell line followed by exposure to g irradiation caused a decrease in the level of p21 WAF1 protein. The p21 WAF1 gene is a direct transcriptional target of p53, and its product inhibits cell proliferation through direct binding to cyclin-dependent kinase (CDK) or subunits of E2F transcription factor, or by interacting with proliferating-cell nuclear antigen (PCNA) to inhibit DNA replication. In DNA-damaged cells, p53 induces p21 WAF1 to arrest cells at G1. When cells have to be released from cell-cycle arrest and undergo apoptosis, p21 WAF1 is cleaved by caspase-3 (Yu et al., 1999) or is degraded. In mammalian cells, p21 WAF1 is an unstable and short-lived protein that exhibits ubiquitination in vivo and proteasome-dependent turnover (Blagosklonny et al., 1996 : Fukuchi et al., 1999 . In our experiments, only a small fraction of p21 WAF1 protein is affected by suppression or overexpression of p53RFP, indicating that additional ubiquitination or proteolysis pathways may regulate the stability of p21
WAF1
. In fact, in humans, the p19 SKP1 /p45 SKP2 /CUL-1 complex is likely to function as an E3 ligase complex that targets p21 WAF1 for ubiquitin-dependent degradation (Yu et al., 1998) . The p21 WAF1 protein can also be degraded by the proteasome without ubiquitin attachment; 20S proteasomes are able to mediate rapid degradation of p21 WAF1 by interacting with the C terminus of p21 WAF1 in the absence of ubiquitin conjugation (Sheaff et al., 2000; Touitou et al., 2001) . Hence, we speculate that the turnover of p21 WAF1 might be regulated by multiple pathways for ubiquitination and proteolysis.
We have shown that p53RFP interacts with p21 WAF1 in vitro and in vivo. Although we have not yet confirmed binding of p53RFP to p21 WAF1 either directly or as a part of a complex, we suspect that p53RFP may function as an E3-ubiquitin ligase or a subunit of E3 ligase complex to ubiquitinate p21 WAF1 for degradation, or that it may serve some function other than signaling proteolysis. The specific cellular function for the association between p53RFP and p21 WAF1 needs to be further characterized. Identification of the physiological substrate and determination of its E2 partner will help us achieve a better understanding of the precise biological role of p53RFP, and also clarify the role of p53 in regulating ubiquitin proteolysis as an apparently novel addition to its tumor-suppressive functions.
Materials and methods

Cell culture
H1299 (lung carcinoma), U373MG (glioblastoma), MCF-7 (human mammary carcinoma), and HCT116 (colorectal carcinoma) cells were purchased from ATCC. All cells were cultured under conditions recommended by their respective depositors. HCT116 p53 wild-type (p53 þ / þ ) and its derivative (p53À/À) lacking p53 were kindly provided by Dr Bert Vogelstein (Howard Hudges Medical Institute, Johns Hopkins University Baltimore, MD, USA).
Northern-blot analysis
Total RNA was extracted at various time points from U373MG cells infected with Ad-p53 or Ad-LacZ, and also from MCF7 cells subjected to DNA-damaging treatments. Total RNAs, isolated using TRIZOL reagent (GIBCO BRL), were further purified to poly(A) þ RNA using mRNA purification kits (TAKARA) according to the manufacturer's instructions. A 2-mg aliquot of each poly(A) þ RNA was separated on a 1% agarose gel containing 1 Â 4-morpholinepropanesulfonic acid buffer and 2% formaldehyde, and transferred onto a nylon membrane. The blots were hybridized with a random-primed 32 P-labeled EST selected from the microarray as being clearly upregulated by p53.
Library screening
To isolate a full-length cDNA of the selected EST, we constructed a cDNA library using poly(A) þ RNA obtained from U373MG cells infected for 48 h with Ad-p53, and screened 1 Â 10 6 independent colonies of this library using the same cDNA fragment that had served as a probe for Northern-blot hybridization.
ChIP assay
ChIP assay was performed using the ChIPs assay kit (Upstate Biotechnology) according to the manufacturer's instruction. In brief, 2 Â 10 6 U373MG cells were seeded onto 10-cm dish, 1 day prior to infection by Ad-p53 at 80MOI. HCT116 and MCF7 cells were treated with adriamycin (1 mg/ml) for 2 h. At 24 h after infection, genomic DNA and protein were crosslinked by adding 1% formaldehyde into the medium and incubated for 15 min at 371C. Cells were lysed in 200 ml of SDS lysis buffer with a protease inhibitor mixture and sonicated to generate DNA fragments with length between 200 and 800 bp. The sonicated cell supernatant was diluted and precleared with salmon sperm DNA/protein A agarose. The precleared supernatant was immunoprecipitated using anti-p53 antibody (DO-7) or anti-FLAG antibody (M2, sigma) as a control antibody, at 41C for 16 h. The immune complexes were precipitated, washed, and eluted. DNA protein were reverse crosslinked at 651C for 5 h. DNA was recovered by phenol-chloroform extraction, ethanol precipitation, and resuspended in 50 ml of TE buffer. In all, 1 ml of each sample was used as a template for PCR amplication (32 cycles) using primer sets flanking the suspected p53-binding site. PCR amplification of a 337 and 472 bp genomic fragment containing p53BS1 and p53BS2 was performed using forward primer p53BS1F 5 0 -GTGCATGG-GAAGTGTTTCTA-3 0 , reverse primer p53BS1R 5 0 -GTGTT GGCCTTAACCCTATC-3 0 , and p53BS2F 5 0 -CTGGTGGG AGGTAATTGGAC, p53BS2R 5 0 -TAGAAGGTGAAGGG GAAGCA, respectively. PCR amplification of the p21 promoter was performed using oligonucleotides 5 0 -ACCTTTC ACCATTCCCCTAC-3 0 (forward) and 5 0 -GCCCAAGGACA AAATAGCCA-3 0 (reverse).
Luciferase assay
The 337 bp fragment including p53BS1 was cloned into pGL3-promoter (Luc-BS1-pro) and pGL3-basic vector (Luc-BS1-ba) (Promega Corp., Madison, WI, USA). To generate reporter constructs with point mutations (Luc-BS1-2 mt-pro and Luc-BS1-2 mt-ba), nucleotide 'T' was introduced into the fourth nucleotide 'C' and the seventh nucleotide 'G' of p53BS1 using Quick Change Site-directed Mutagenesis Kit (stratagene). H1299 (p53 null) cells grown in six-well culture plates were transfected with 1 mg of each reporter constructs, 100 ng of pRL-CMV internal control vector, and 200 ng of wt-p53 or mt-p53, using FuGENEt6 Transfection Reagent (Roche). Quantification of both luciferase activities and calculations of relative ratios were carried out manually with a luminometer.
Generation of MCF-7 cells with inducible p53RFP expression
Tet-Off gene expression system and MCF-7 Tet-Off cell line (Clontech) were employed to generate a tetracycline-inducible p53RFP stable transfectant. The entire coding sequence of p53RFP cloned into pTETpuro response plasmid (Clontech) was transfected into MCF-7 Tet-Off cell line and selected in the presence of 1 mg/ml puromycin. Resistant clones were screened for the expression of p53RFP in the absence of doxycycline by p53RFP immunoblotting. The transcription of p53RFP was observed in the absence of doxycycline (Dox þ ) but not in the presence of doxycycline (DoxÀ). Clones were maintained continuously in Dox þ condition.
Western-blot analysis
U373MG and H1299 cells were infected with Ad-p53 at MOI 40 at various time points. Total cell lysates were prepared in RIPA buffer (1% NP40, 50 mm Tris-HCl (pH 8), 150 mm NaCl, 0.5% DOC, 0.1% SDS, and complete protease-inhibitor cocktail (Roche). Aliquots (20 mg) of soluble proteins were loaded on SDS-polyacrylamide gels and transferred to nitrocellulose membranes (HybondECLt). The membranes were blocked with 5% nonfat milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) and incubated with each antibody for 1 h at room temperature or overnight at 41C. The blots were then hybridized with HRP-conjugated secondary antibody (Santa Cruz Biotechnology), and detected using the ECL method.
Construction of plasmids and fusion proteins
The entire coding sequence of p53RFP, or p53RFP with hemagglutinin (HA) or FLAG tags at the N or C termini, respectively, were cloned into XhoI-and BamHI-digested pcDNA 3.1 þ vector (invitrogen). Full-length p21 WAF1 cDNA p53RFP, a p53-inducible RING-finger protein C-C Ng et al was inserted into EcoR1-and Sac1-digested pcDNA 3.1 þ vector. The HA-ubiquitin expression vector was a gift from Dr K Miyazono (The Cancer Institute of Japanese Foundation for Cancer Research). To generate an in-frame His-tag recombinant protein (p53RFP-delTm-His) or glutathione Stransferase fusion protein (GST-p53RFP-delTm), a truncated cDNA of p53RFP with deletion of the transmembrane domain was amplified by PCR and subcloned into EcoRI-and NotIdigested pET21a (Invitrogen) or pGEX-5x-1 (Pharmacia Biotech) plasmid, respectively.
Immunofluorescent staining
p53RFP constructs, HA-tagged at the N or C termini, respectively, were transiently transfected into COS7 cells. At 24 and 48 h after transfection, the cells were fixed with 4% paraformaldehyde in PBS, rendered permeable with 0.1% Triton X-100 in PBS for 3 min, and covered with blocking solution (3% BSA and 2.5% secondary antibody animal serum in PBS) for 60 min at room temperature. The cells were then incubated for 1 h with rabbit anti-HA antibody (MBL) or mouse anti-Golgi 58k antibody (Sigma) diluted 1 : 300 in blocking solution followed by incubation with FITC-conjugated goat anti-rabbit and Texas-Red-conjugated anti-mouse secondary antibody diluted 1 : 1000, and viewed with an ECLIPSE E600 microscope (Nikon).
Antibodies
Polyclonal antibodies against p53RFP protein were generated in rabbits using truncated recombinant p53RFP protein synthesized in bacteria. The antibodies were purified by passage through antigen-affinity columns. Mouse monoclonal anti-p53 (DO-1), mouse anti-p21 WAF1 (Ab-1, Ab-5) (Oncogene Research Products), mouse monoclonal anti-b-actin (Sigma), mouse anti-FLAG (Sigma), rat anti-HA antibody (Roche), mouse anti-CDK4 (PharMingen), rabbit anti-p21 WAF1 (c-19) (Santa Cruz Biotechnology), and rabbit anti-MDM2 (Santa Cruz Biotechnology) antibodies were used for Western-blot analyses according to the manufacturers' recommended concentrations.
Cell-damage experiments
HCT116 p53 wild-type (p53 þ / þ ) and the derivative (p53À/ À) cells were treated with adriamycin (1 mg/ml) for 2 h. MCF7 cells were subjected to g (50 Gy) or UV radiation (10 J/m 2 ), or treatment with adriamycin (1 mg/ml) for 2 h. To examine expression of p53RFP, a Northern blot was prepared using RNAs isolated from cells at various time points after each treatment.
Immunoprecipitation and ubiquitination
In all, 6 mg of FLAG-tagged p53RFP and 2 mg of HA-tagged ubiquitin expression vector were transfected using FuGENE 6 transfection reagent (Roche) into 2 Â 10 6 H1299 cells seeded 1 day before. The cells were harvested 24 h after transfection and lysed in 1 ml of 0.5% NP40 buffer (0.5% NP40, 50 mm TrisHCl (pH 8), 150 mm NaCl, 2 mm EDTA, 2 mm MG132, and complete protease-inhibitor cocktail). The lysates were immunoprecipitated with mouse monoclonal anti-FLAG M2-antibody, rat anti-HA antibody, or normal mouse or rat IgGs (Santa Cruz Biotechnology). After four rounds of washing with lysis buffer, the immunoprecipitates were analysed on Western blots using rabbit anti-p53RFP polyclonal antibody and rat anti-HA antibody.
Overexpression of p53RFP in HCT116 cells followed by g irradiation HCT116 cells (2.5 Â 10 6 ) were transfected with 6 mg of p53RFP expression vector or mock vector. At 10 h after transfection, the cells were exposed to 14 Gy g radiation. Lysates from cells harvested 24 and 48 h after g irradiation were subjected to Western blotting.
Antisense oligonucleotides
To inhibit the expression of endogenous p53RFP, we prepared an S-labeled antisense oligonucleotide (AS, 16mers: GAGCC-CATCAGCCTGT) flanking the initiation codon of p53RFP and, as a control, sense oligonucleotide (S1, 16mers: ACAGGCTGATGGGCTC). Each oligonucleotide (1 mm) preparation was transfected into H1299 cells using Lipofectin reagent (Gibco-BRL); after incubation for 4 h, the cells were infected with Ad-p53 for another 12 or 24 h.
Coimmunoprecipitation assay
H1299 cells (1.5 Â 10 6 ) were cotransfected with 2 mg of p21
WAF1
plasmid and 6 mg of C-HA-p53RFP plasmid for about 28 h, or infected with Ad-p53 at MOI 50 for 24 h. At 6 h before harvest, 20 mm MG132 (CALBIOCHEM), a proteasome inhibitor, was added to the culture medium. Harvested cells were lysed using 0.5% NP40 lysis buffer. Immunoprecipitation with anti-HA and anti-p21 WAF1 (Ab-1) antibodies was carried out for a cotransfection experiment, whereas anti-p53RFP antibody was used to precipitate endogenous p53RFP. Immunoprecipitates were resolved on SDS-PAGE gels and subjected to Western blotting.
GST fusion protein pull-down assay
A 2mg aliquot of p21 WAF1 plasmid was transfected into 1.5 Â 10 6 H1299 cells for 24 h. Cells were lysed using 1 ml lysis buffer (0.5% NP40, 20 mm Tris-HCl (pH 8), 200 mm NaCl, 1 mm EDTA, and complete protease-inhibitor cocktail). Precleared lysates were incubated with glutathione sepharose beads and equimolar amounts of either purified GST-p53RFP fusion protein (GST-p53RFPdelTm, 5 mg) or GST protein (2.5 mg) for 2 h at 41C with rotation. After the beads were washed four times with lysis buffer, bound proteins were eluted using 50 ml SDS sample buffer and analysed by Western blotting using anti-p21 WAF1 (Ab-1) antibody.
2D Western-blot analysis
H1299 cells were prepared as for the sense and antisense oligonucleotide experiments (24 h). The cells were lysed on ice with buffer containing 4% CHAPS (sigma), 8 m Urea (Wako), 2% Pharmalyte 3-10 (Amersham Pharmacia), sonicated, and then centrifuged at 15 000 r.p.m. for 20 min. Briefly, firstdimensional isoelectric focusing was performed by separating 400 mg of protein (in which 40 mg of protein was labeled with Cy-5) in 340 ml IEF solution on 18 cm 3-10NL IPG strips (Amersham Pharmacia) using an Amersham IPGphor unit. The strip was then subjected to a two-step equilibration in dithiothreitol (DTT) and iodoacetamide buffers before proceeding to second-dimension SDS-PAGE. SDS-PAGE was performed on 1.0 mm 12% polyacrylamide gel using Amersham Hoefer SE600 unit and then transferred to nitrocellulose membrane. Protein spots labeled by Cy-5 on the sense and antisense membranes were scanned as a quantity control and, subsequently, Western blotting was carried out.
In vitro ubiquitination assay
The ubiquitination assay of GST-p21 recombinant protein was carried out using His-p53RFP fusion protein without transmembrane domain (His-p53RFP(FdelTm)), and rabbit reticulocyte lysate as a source of E1 and E2 as follows: 3 mg of GSTp21 or 3 mg of GST was incubated with or without 3 mg of Hisp53RFP(FdelTm), 25 mm MG132, and 15 ml of rabbit reticulocyte lysate (Promega) in a reaction mixture (300 ml) containing 40 mm Tris-HCL, pH 7.5, 5 mm MgCl 2 , 2 mm ATP, 2 mm DTT, 300 ng/ml of ubiquitin (sigma), at 301C for 120 min. GST-p21 recombinant protein was then pulled down using glutathione sepharose beads. The beads were washed and bound proteins were eluted using 50 ml SDS sample buffer and analysed by Western blotting using anti-p21 WAF1 antibody.
